The AIDS vaccine "Immunity" scheduled to be distributed free of charge will finally enter the clinical trial

Project to develop AIDS (AIDS) vaccine using data analysis technology "Immunity"Is finally reaching the clinical trial stage, aiming for completion in 2016Cloud FundingWe are recruiting funds.

Immunity Project
https://pledge.immunityproject.org/the-free-hiv-aids-vaccine


HIV (human immunodeficiency virus)Is a virus that infects immune cells that work to protect the human body from pathogens, immunodeficiency, whose immune function decreases as a result of infection with HIV,AIDS (Acquired immunodeficiency syndrome)It is called "vaccineIt is famous as "incurable disease" which is difficult to develop.

To overcome such AIDS, "Immunity" is a project to develop HIV vaccines by computerized "data analysis technology".

Immunity Project Crowdfunding Video - YouTube


Dr. Reed and Loversman of Stanford University who is representative of the Immunity project. Immunity is a collaborative project by Stanford University, Harvard University, MIT, San Francisco Venture Business Association.


Dr. Lovelman's hand is developing HIV vaccine "Immunity".


Development of Immunity began as the research team of Dr. Lovelmann discovered the presence of people (controllers) with HIV antibodies at a rate of 1 in 300 people. By research, it turned out that the controller put HIV in a dormant state so as not to cause AIDS. Therefore, Dr. Lovelman 's research team tried to develop an HIV vaccine by analyzing the immune system of the controller, analyzing what kind of mechanism the HIV is in a dormant state and imitating it .


At that time, Dr. Lovesman used the spam filtering software algorithm developed by Microsoft e - Science Laboratories. Since Dr. Lovelsman was both a doctor and a computer scientist, he analyzed genetic data on HIV genetic data and the controller's immune system with a computer and analyzed its biological mechanismreverse engineeringBy doing so, I tried to develop an HIV vaccine.


Dr. David Hackerman, who developed this data analysis algorithm in collaboration with Microsoft, is a research associate with Dr. Loversman who has worked at Stanford University for several years and also participates in the Immunity project.

The prototype of the Immunity vaccine developed using the data analysis technology already used the mouseSucceeded to make HIV dormant in animal experiments. The effect has been demonstrated.


The Immunity project is known for HIV preventive awareness activitiesUntil There's A CureWorking in conjunction with ... ...


Y CombinatorSuccessfully to receive assistance.


By November 2014FDAWe are planning to begin Phase I clinical trials in December 2014.


There are more than 35 million HIV-infected people in the world, 70% of which live in sub-Saharan Africa. 6300 people are newly infected with HIV everyday, and more than 4000 people died of AIDS everyday.


Immunity can be easily transported to Africa because it is not necessary to store frozen. Also, there is no need to sacrifice daily living for the treatment of HIV, a vaccine that does not require permanent treatment.

The Immunity project completes the HIV vaccine,Free distribution to people infected with HIVintend to do something.


Although the Immunity project which the clinical trial will finally start from December 2014, it is necessary to acquire further research, clinical trial, permission before completion, and it will require 480,000 dollars (about 500 million yen) for it .


The Immunity project is planning to collect vaccine development expenses using the cloud funding method, and is now looking for investment at the official website. The investment is possible from $ 50 (about 5100 yen), and it is given a supporter certificate which can access the special site of the Immunity project with a capital of 100 dollars (about 10,000 yen), and it is financed with a capital of 250 dollars (about 26,000 yen) You can get a title of Immunity Fellow and a T - shirt.


Furthermore, you can issue a certificate as a team member of the Immunity project with a capital of 1000 dollars (about 100,000 yen), and you can get a tour of the Immunity project's laboratory with a contribution of 10,000 dollars (about 1,300,000 yen) You can invite and you are entitled to a lecture by the Immunity project research team, although it is limited to the US with a capital of 50,000 dollars (about 5.15 million yen), with a capital of 100,000 dollars (about 10.3 million yen) You will be eligible to participate in Phase I clinical trials in Africa.

The deadline for financing the Immunity project is until March 31, 2014.